- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.12.25 | Why Inhibrx's Recent Strength May Not Be Built to Last | 1 | Benzinga.com | ||
| 17.12.25 | Inhibrx: Citizens bekräftigt "Market Perform"-Rating wegen unzureichender Daten | 11 | Investing.com Deutsch | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures | 3 | Investing.com | ||
| 17.12.25 | Inhibrx Advances INBRX-106, Ozekibart Programs, Key Milestones Expected Next Year | - | RTTNews | ||
| 16.12.25 | Inhibrx provides updates on cancer treatment clinical trials | 1 | Investing.com | ||
| 16.12.25 | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.11.25 | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen | 6 | Investing.com Deutsch | ||
| 14.11.25 | Inhibrx Biosciences GAAP EPS of -$2.28 | 2 | Seeking Alpha | ||
| 14.11.25 | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | 224 | PR Newswire | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| 24.10.25 | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | 723 | AFX News | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 24.10.25 | Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? | 6 | Benzinga.com | ||
| 23.10.25 | Inhibrx stock soars after positive cancer drug trial results | 12 | Investing.com | ||
| 23.10.25 | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10.25 | Inhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion ... | 1.080 | PR Newswire | Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free... ► Artikel lesen | |
| 22.08.25 | Citizens JMP reiterates Market Perform rating on Inhibrx Biosciences stock | 2 | Investing.com | ||
| 13.08.25 | Inhibrx Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.08.25 | Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results | 508 | PR Newswire | SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second... ► Artikel lesen | |
| 14.05.25 | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial Results | 324 | PR Newswire | SAN DIEGO, May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first... ► Artikel lesen | |
| 17.03.25 | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results | 385 | PR Newswire | SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,250 | 0,00 % | Schlägt Thermo Fisher zu?: Qiagen: Übernahmegerüchte schicken die Aktie auf Kursachterbahn | © Foto: Rafael Henrique - picture allianceÜbernahmegerüchte um den Diagnostikspezialisten Qiagen sorgten am Dienstag für einen rekordverdächtigen Kursanstieg. Am Mittwoch kommt die Aktie wieder etwas... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 93,79 | +3,04 % | Guggenheim raises Structure Therapeutics stock price target to $140 on obesity drug confidence | ||
| CG ONCOLOGY | 57,13 | +4,46 % | What Analysts Are Saying About CG Oncology Stock | ||
| COGENT BIOSCIENCES | 39,900 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,64 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ALUMIS | 26,680 | 0,00 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| PRAXIS PRECISION MEDICINES | 312,60 | -3,54 % | Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus | ||
| KYMERA THERAPEUTICS | 70,74 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) | ||
| BEAM THERAPEUTICS | 31,120 | 0,00 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| KINIKSA PHARMACEUTICALS | 41,830 | +1,95 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,850 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| ERASCA | 10,050 | 0,00 % | Erasca, Inc.: Erasca Announces Proposed Public Offering of $150 Million of Common Stock | SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| VERA THERAPEUTICS | 45,770 | +2,10 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| IMMUNOME | 24,870 | +4,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TANGO THERAPEUTICS | 12,500 | -0,08 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
INHIBRX BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,02 % bei einem Aktienkurs von 75,10 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.